Biotech company DNActive receives a €372,500 round of funding

, , , ,
Integral service around a transaction
BY : Diego GutiérrezMarch Fri, 2019

DNActive, which specialises in the development of genetic tests and the manufacture of products based on the genetics of patients, has recently received a round of funding. Its investor has been the crowdfunding platform, which has injected 372,500 euros.

Following this analysis, we have decided to investigate the biotechnology sector with the sale of companies most prominent in 2019.

Funding round for DNActive

Founded in 2016 and based in Granada, DNActive Genetic Analysis is a bio-health company specialising in developing genetic tests and subsequently manufacture tailor-made products based on the genetic characteristics of the individual. After this process, they market disease prevention plans, nutritional itineraries, adapted training, customised supplementation or cosmetics, among others. As distribution channels for these products they use clinics and laboratories, pharmacies and their own website.

DNActive's operating income in 2017 was €69,801 and in the first half of 2018 it doubled, 150,221 euros. Moreover, in early 2018, they were awarded a Horizon 2020 grant of 46,000 euros.

On 6 March 2019, it closed a round of financing via crowdfunding for an amount of 372,500 euros. Its investor has been the crowdfunding platform

Interestingly, all the seed money goes to DNActive's marketing. The investment is divided into Media, face-to-face and national promotional marketing and within them, newsletter campaigns, sponsorships or merchandising, among others, will be carried out.

You can check all the detailed information about the operation on this page of

Selling companies internationally

After looking at DNActive, we will then go on to we review the operations of sale of companies which have already been confirmed in the biotechnology sector in 2019. You can also take a look at a study we subsequently conducted on the rounds that were being confirmed in 2018 in this post.

The most significant sales transactions in 2019 are as follows:

1. MyoScience

MyoScience is dedicated to development and commercialisation of dermatological technology products. It was founded in 2005 and is based in Redwood City, California.

On 5 March, we learned of the sale agreement between MyoScience and Pacira Pharmaceuticals. Under the terms of the agreement, Pacira will pay up to $220 million in total, being 120 in cash upfront and an additional 100 on reaching targets. The sale is expected to close in early April 2019.


Founded in 2005, MolecularMD Corporation develops and markets specialised molecular diagnostics for oncology applications. Its tests are designed to enable the selection, monitoring and management of patients treated with molecularly targeted cancer therapies.

ICONa provider of outsourced drug development services, acquired MolecularMD on 21 February. The amount of the deal has not been disclosed.

3. Auris Health

Auris Health (San Carlos, California) is dedicated to the development of robotic technology for medical applications. The company designs a novel dual-arm microsurgical system for ophthalmic surgery. The company is committed to transforming medical intervention by integrating robotics, micro instrumentation, endoscope design, sensing and data science into one platform.

On 13 February, we learned of the sale of the company to Jhonson & Jhonson. The amount of the operation reached the astonishing figure of $3.4B.

4. Taconic Biosciences

We found this company curious. Taconic Biosciences for more than 6 decades has been a provider of research models and supporting the efforts of the research community to reduce the use of animals. Through dedicated teams of scientific and project management professionals, they work with clients to design and execute project plans to meet their research objectives.

The global private equity and alternative asset investment firm H.I.G. Capital executed leveraged buyout of Taconic on 7 February. The amount of the transaction has not been disclosed.

5. Labcyte

Founded in 2000, Labcyte is a laboratory with an innovative approach to dispense small volumes of liquids for life science applications. It is known for its Echo® acoustic droplet ejection technology, which uses sound waves to transfer small amounts of liquid with unrivalled speed and precision.

This innovation has led to the sale of the company to Beckman Coulter Life Sciences. The transaction took place on 30 January and the amount was not confirmed.

The M&A Professionals

Meet our services



Do you want to be up to date?


Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?